Reduced hypoxia risk in a systemic sclerosis patient with interstitial lung disease after long-term pulmonary rehabilitation

Clinical Medicine Insights: Case Reports

Volumn 4, Issue , 2011, Pages 53-56

  Mugii, Naoki ^a   Someya, Fujiko ^a,b   Hasegawa, Minoru ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Exercise; Hypoxia; Interstitial lung disease; Systemic sclerosis; Walking

Indexed keywords

BOSENTAN; CORTICOSTEROID; OXYGEN; PROSTACYCLIN; SILDENAFIL;

ADULT; ARTICLE; BLOOD GAS ANALYSIS; CARDIOPULMONARY FUNCTION; CASE REPORT; DISEASE SEVERITY; DRUG DOSE INCREASE; EXERCISE; FORCED VITAL CAPACITY; HUMAN; HYPOXIA; INTERSTITIAL LUNG DISEASE; LONG TERM CARE; LUNG ARTERY PRESSURE; LUNG DIFFUSION CAPACITY; MALE; MUSCLE TRAINING; OXYGEN SATURATION; PULMONARY REHABILITATION; SKIN ULCER; SYSTEMIC SCLEROSIS;

EID: 80555136816     PISSN: 11795476     EISSN: 11795476     Source Type: Journal    
DOI: 10.4137/CCRep.S8071     Document Type: Article

References (13)

1. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: An analysis of 17 patients. Br J Rheumatol. 1996;35: 989-93.
2. Goh NSL, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis. Am J Respir Crit Care Med. 2008;177:1248-54.
3. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008;63:549-54.
4. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fbrosis. Respirology. 2008;13:394-9.
5. Ferreira A, Garvey C, Connors GL, et al. Pulmonary rehabilitation in interstitial lung disease. Chest. 2009;135:442-7.
6. Garrod R, Lasserson T. Role of physiotherapy in the management of chronic lung diseases: An overview of systematic reviews. Respir Med. 2007;101: 2429-36.
7. Foglio K, Bianchi L, Bruletti G, et al. Seven-year time course of lung function, symptoms, health-related quality of life, and exercise tolerance in COPD patients undergoing pulmonary rehabilitation programs. Respir Med. 2007; 101:1961-70.
8. Holland AE, Hill CJ, Rasekaba T, Lee A, Naughton MT, McDonald CF. Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2010;91:221-5.
9. Enright PL, McBurnie MA, Bittner V, et al. The 6-min walk test: a quick measure of functional status in elderly adults. Chest. 2003;123:387-98.
10. Nava S. Rehabilitation of patients admitted to a respiratory intensive care unit. Arch Phys Med Rehabil. 1998;79:849-54.
11. Vogiatzis I, Terzis G, Nanas S, et al. Skeletal muscle adaptations to interval training in patients with advanced COPD. Chest. 2005;128:3838-45.
12. King TE, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fbrosis. Am J Respir Crit Care Med. 2008;177:75-81.
13. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epo-prostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132:425-34.